Navigation Links
For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
Date:7/8/2009

WALTHAM, Mass., July 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the treatment of dyslipidemia patients who fail to reach LDL goal, surveyed physicians are increasingly switching patients to a more potent statin --- most notably AstraZeneca's Crestor --- rather than adding Merck/Schering-Plough's Zetia (ezetimibe) or switching to Merck/Schering-Plough's Vytorin (simvastatin/ezetimibe). These changes have occurred as a result of the JUPITER trial as well as the ENHANCE and SEAS trials.

The new Physician & Payer Forum report entitled Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? finds that the share of patients prescribed Vytorin and Zetia by surveyed PCPs in primary prevention has declined by three and one percentage point respectively since the conclusion of the ENHANCE and SEAS clinical trials. However, in primary prevention, the share of patients prescribed Vytorin and Zetia by cardiologists has declined by seven and four percentage points respectively during the same time period.

The report also finds that a majority of managed care organizations' (MCOs) pharmacy directors have taken action as a result of the SEAS and ENHANCE trials. The ENHANCE trial showed that Vytorin was no more effective than the less expensive generic simvastatin in reducing carotid intima-media thickness. The report's survey results indicate that Vytorin was moved to a less favorable tier in 30 percent of both commercial plans and Medicare PDPs, although these actions may have been based on some misconceptions about Vytorin's efficacy.

"Although two-thirds of surveyed pharmacy directors indicate that they are aware of the results of the ENHANCE trial, their understanding of the results appears somewhat flawed and favors simvastatin," said Decision Resources Analyst Jeremy Goldman, M.D. "Only one-quarter of all surveyed pharmacy directors know that ENHANCE showed Vytorin was more effective at reducing LDL cholesterol than simvastatin. The negative press surrounding the results of the ENHANCE trial appears to have left an incorrect and unfavorable impression about Vytorin on many MCO pharmacy directors."

Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? is based on a U.S. survey of 70 primary care physicians, 70 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Survey: Americans Fear Paying for Cancer Treatment As Much As Dying of the Disease
2. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
3. U.S. Food and Drug Administration and Xanodyne Agree on a Plan to Keep Propoxyphene-Containing Products Available as Treatment Options for the Management of Mild to Moderate Pain
4. Rice University teams award-winning device could benefit treatment of hand injuries
5. June 2009 Mayo Clinic Health Letter Highlights Probiotics, Carotid Artery and Breast Cancer Treatments
6. New strategies to improve treatment and ultimately prevent heart failure in children
7. ICSI Plans Symposium on New Depression Treatment Program That Is Improving Patient Outcomes Five-Fold Over Typical Primary Care
8. Major Firms Eyeing CBMS Development of New Glaucoma Treatment
9. New, More Effective Acne Treatment Program Launches
10. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
11. Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology: